A new malaria vaccine developed by researchers at the Oxford University and scientists from Burkina Faso has been shown to be highly effective in trials in Africa; the vaccine hold the possibility of reducing the death toll of 400,000 persons being killed by malaria, most of who are small children every year.
The vaccine showed up to 77% efficacy in a trial of 450 children in Burkina Faso over 12 months. It is the first vaccine to meet the WHO goal of 75% efficacy against the mosquito-borne parasite disease.
TOS News gathered that more than 4,800 children below three years will be recruited in the next trial which will take place in Burkina Faso, Mali, Kenya and Tanzania.
According to the researchers, the vaccine will be manufactured at large scale and low-cost.